Dose Escalation Study of TAK-117 (MLN1117) in Subjects With Advanced Cancer

Phase 1 Completed 125 enrolled Millennium Pharmaceuticals, Inc.

Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the maximum tolerated dose (MTD) and/or optimal biologic dose(OBD), safety and tolerability, dose-limiting toxicity (DLT) of TAK-117 when administered orally in subjects with advanced solid malignancies.

Timeline

Start: 2011-10
Primary completion: 2015-07
Completion: 2016-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Serabelisib	Small molecule	—	Oral

Dose Escalation Study of TAK-117 (MLN1117) in Subjects With Advanced Cancer

Summary

Timeline

Drugs

Indications